Bristol-Myers Squibb Canada Co v Pharmascience Inc, 2021 FC 1

Trimble Solutions Corporation v Quantum Dynamics Inc, 2021 FC 63

Loblaws Inc. v. Columbia Insurance Company, 2021 FCA 29

Betser-Zilevitch v. Petrochina Canada Ltd, 2021 FC 151

Smart Cloud Inc. v. International Business Machines Corporation, 2021 FC 236 (CanLII)

Double Diamond Distribution Ltd. v. Crocs Canada, Inc., 2021 FCA 47 (CanLII)

TBV Productions, LLC v Doe, 2021 FC 181

Fresenius Kabi Canada Ltd. (“Fresenius”) entered into a confidential licensing agreement with AbbVie Biotechnology Ltd. (“AbbVie”) authorizing Fresenius to perform certain acts under AbbVie’s listed patents in respect of HUMIRA™ (adalimumab). Fresenius sought to rely on AbbVie’s consent under subsection 7(2) of the Patented Medicines (Notice of Compliance) Regulations (the “Regulations”) in respect of its New Drug Submission for its biosimilar drug product IDACIO™.

The Plaintiffs [Shake Shack] brought an action for trademark infringement against the Defendant [Chic Shack]. The parties agreed to enter into a Court-assisted mediation governed by Rules 387 to 389 of the Federal Courts Rules. Shake Shack was of the view that, at the end of the mediation, the parties had an agreement to settle the action.

Prior to the case at bar, the Federal Court granted Bombardier Recreational Products Inc (“Bombardier”) a permanent injunction as the result of its infringement action. The infringer, Arctic Cat Inc (“Arctic Cat”), sought a stay of the injunction pending an appeal of the decision. However, the Federal Court of Appeal denied the stay as it was not satisfied that irreparable harm was established and the balance of convenience favoured Bombardier.